Selin Carkaci MD, Presenter: Consultant, Hologic, Inc

Beatriz E. Adrada MD, Abstract Co-Author: Nothing to Disclose

Amado B. Del Rosario DO, Abstract Co-Author: Nothing to Disclose

Gary J. Whitman MD, Abstract Co-Author: Nothing to Disclose

• Monitoring response to treatment is a key element in the management of breast cancer. • Assessing response to chemotherapy prior to surgery can provide prognostic information to help guide follow-up care. • Breast imaging plays a role in evaluating tumor response and clinical decisions in the neoadjuvant setting. • Breast MRI correlates more accurately with pathologic response when compared to clinical exam, ultrasound and mammography. • It is important to know the limitations of imaging modalities as well as false positives and false negatives when using imaging to monitor response. • Different histologic types of breast cancer respond to neoadjuvant chemotherapy to varying degrees. • Imaging protocols for evaluation of response should be tailored based on the histology and imaging features of the primary breast cancer. • Emerging technologies have the potential to provide specificity for assessing response to treatment.  

• Introduction • Neoadjuvant chemotherapy • The Response Criteria in Solid Tumors (RECIST) • Comparison of imaging modalities to assess response to neoadjuvant chemotherapy • Challenges in assessing response: False negatives and false positives • Tumor response to neoadjuvant chemotherapy by histologic type • Emerging technologies and future directions • Conclusion  

http://abstract.rsna.org/uploads/2014/14015176/14015176_o9io.pdf

Carkaci, S, Adrada, B, Del Rosario, A, Whitman, G, Current Concepts in Evaluation of Response to Neoadjuvant Chemotherapy in Breast Cancer.  Radiological Society of North America 2014 Scientific Assembly and Annual Meeting, - ,Chicago IL. http://archive.rsna.org/2014/14015176.html